Methotrexate is one of the oldest chemotherapeutics and a potent and specific inhibitor of dihydrofolate reductase (Williams et al. 1979), leading to THF deficiency, accounting for its antiproliferative properties. This evidence concerns the gene DHFR and hyperinsulinemic hypoglycemia, familial, 4.